Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status (Q37865580)

24 August 2017

Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status (English)

1 reference

24 August 2017

0 references

3

Ashley B Grossman

1 reference

24 August 2017

Ann I McCormack

1

1 reference

PubMed ID

21496012

24 August 2017

John A H Wass

series ordinal

2

1 reference

24 August 2017

18 April 2011

1 reference

European Journal of Clinical Investigation

24 August 2017

1 reference

24 August 2017

41

1 reference

24 August 2017

10

1 reference

24 August 2017

1133-1148

1 reference

Pathology of invasive pituitary tumors with special reference to functional classification

24 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Clinical review: Diagnosis and management of pituitary carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Pituitary carcinoma: a clinicopathologic study of 15 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Malignant pituitary tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Pituitary carcinoma occurring as middle ear tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Management of aggressive pituitary adenomas: current treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Triazene compounds: mechanism of action and related DNA repair systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Phase II study of protracted daily temozolomide for low-grade gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

New (alternative) temozolomide regimens for the treatment of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Inhibition of angiogenesis by non-toxic doses of temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

A rare case of aplastic anemia caused by temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Temozolomide: a novel oral alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Hypersensitivity pneumonitis associated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Variability and regulation of O6-alkylguanine-DNA alkyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Targeted modulation of MGMT: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Genomic and molecular profiling predicts response to temozolomide in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Phase II study of extended-dose temozolomide in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Long-term response of pituitary carcinoma to temozolomide. Report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Treatment of Nelson's syndrome with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Use of temozolomide in aggressive pituitary tumors: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Temozolomide-induced inhibition of pituitary adenoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

MGMT immunoexpression in aggressive pituitary adenoma and carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02520.X

10.1111/J.1365-2362.2011.02520.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21496012